TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05593575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+SPH3127matching placebo+valsartan matching placebo
Description: 1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+SPH3127matching placebo+valsartan matching placebo
Description: 2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127+valsartan matching placebo
Description: 4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study: NCT05779293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive auricular vagus nerve stimulation
Description: The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks.
Study: NCT05593575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 matching placebo+valsartan
Description: 4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
Study: NCT04859023

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva sample combined to an anterior nare self-swabbing (Self-samples)
Description: Tested by antigenic test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva sample (Self-sample)
Description: Tested by RT-PCR.
Study: NCT06053424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ14132516
Description: Radioligand
Study: NCT06356584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Immunotherapy
Study: NCT06230380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with autofluorescence
Description: In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
Study: NCT05821283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise program consisting of supervised exercise and physical activity
Description: The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise program consisting of only supervised exercises.
Description: The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
Study: NCT05681520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEEPS
Description: Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
Study: NCT05456685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Description: Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
Study: NCT06004973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR Particles
Description: A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
Study: NCT04408638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
Study: NCT04859023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of SARS-COV-19 knowledge
Description: collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of acceptability of the different self-samples.
Description: collection of : assessment and acceptability of the tolerance of self-samples.
Study: NCT06655558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom knee orthosis
Description: The custom knee orthosis will be worn for 8 weeks.
Study: NCT04778631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
Study: NCT06657118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided arthrocentesis of tempromandibular joint
Description: * Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anatomically guided arthrocentesis of tempromandibular joint
Description: * Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours
Study: NCT06662084

Intervention type: DIAGNOSTIC_TEST
Intervention: phenotype
Description: Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping.

Intervention type: DIAGNOSTIC_TEST
Intervention: phenotype
Description: Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping.
Study: NCT06661148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-003
Description: Intravenous (IV) infusion.
Study: NCT06659458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene sequencing
Description: Subjects will have their DNA sequenced within and around the EGFR gene.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene sequencing
Description: Subjects will have their DNA sequenced within and around the EGFR gene.
Study: NCT06661564

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)
Description: Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)
Description: Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)
Description: Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
Study: NCT06215560

Intervention type: OTHER
Intervention: PDMP Check CDS
Description: Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
Study: NCT06075745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMV-MVA Triplex
Description: The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
Study: NCT06661564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of a blood sample (5 mL) for blood biomarkers analysis
Description: Collection of a blood sample (5 mL) for blood biomarkers analysis.
Study: NCT06659380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)
Description: Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole + Cal95
Description: Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Floragyn® probiotic tablets (Lapi, Indonesia)
Description: Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
Study: NCT06660628

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Large Segmentation Radiotherapy
Description: Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Large Segmentation Radiotherapy
Description: Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIBH
Description: Deep Inspiration Breath Hold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface guided radiation therapy
Description: The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser alignment
Description: Laser systems for virtual simulation and patient positioning in radiotherapy
Study: NCT05551559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery
Study: NCT06075745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CMV-MVA Triplex
Description: Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
Study: NCT06476561

Intervention type: OTHER
Intervention: - Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D
Description: The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance.
Study: NCT06104800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet with red meat
Description: Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet without red meat
Description: Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
Study: NCT06470191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007： Subcutaneous injection was administered on days 1 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin Capsules
Description: Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
Study: NCT06388564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be administered at protocol defined dose.
Study: NCT06254846

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample, 1st stream
Description: Use of the Colli-Pee® device for collecting the first urine stream

Intervention type: OTHER
Group type: OTHER
Intervention: Cervico-vaginal swab
Description: Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged).
Study: NCT05670067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary tuberosity bone graft (autogenous graft)
Description: the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone graft (xenograft)
Description: xenograft is bone graft material that is obtained from porcine, bovine or equine source
Study: NCT06517394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovering Together after Cardiac Arrest
Description: The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
Study: NCT06660628

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: free breathing
Description: Patients breathe calmly while radiotherapy instead of holding their breath.
Study: NCT04769440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mg sulphate
Description: mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
Study: NCT05920356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous administration
Study: NCT06039865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Participants only receive usual care from the sleep center.
Study: NCT06445985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Physiotherapy led pool session
Study: NCT04997018

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted.
Study: NCT05957432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Black Seed Oil Cap/Tab
Description: possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan, Amoxicillin and Clarithromycin
Description: H pylori vonoprazan based treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan, Amoxicillin and Clarithromycin
Description: H pylori vonoprazan based treatment